New Findings in Brain Metastasis Treatment

The ROADS trial, co-led by Jeffrey Weinberg, M.D., professor of Neurosurgery, and Thomas Beckham, M.D., Ph.D., assistant professor of CNS Radiation Oncology, has revealed that tile-based radiation therapy (TBRT) dramatically outperforms the current standard of care for patients with newly diagnosed brain metastases. The trial, presented at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, compared TBRT against postoperative SRT.

Key Findings and Implications

Dramatic Improvement in Survival Rates: In the landmark ROADS trial, patients treated with TBRT achieved a median overall survival of 42.5 months, more than doubling the 17.6 months observed in the standard SRT group. This significant increase in survival is attributed to the immediate and localized delivery of radiation therapy upon tumor removal.

Near-Elimination of Recurrence: One year following surgical resection, patients treated with TBRT experienced a 1.3% rate of tumor recurrence at the surgical site. In contrast, the standard SRT arm faced a 15.4% recurrence rate, underscoring the effectiveness of the tile-based approach in preventing residual cancer cell proliferation.

Overcoming Logistical Delays: Standard postoperative SRT requires patients to heal from surgery and navigate scheduling hurdles, resulting in a median timeline of 32 days before treatment begins. This delay can cause roughly 20% of standard patients to never receive their planned radiation at all. The TBRT tile system completely bypasses these barriers by ensuring 100% treatment delivery on day one, directly on the operating table.

Technical Details and Mechanism

TBRT utilizes an FDA-cleared low-dose brachytherapy device featuring postage-stamp-sized collagen tiles embedded with evenly spaced cesium-131 seeds. These tiles are “wallpapered” directly to the raw cavity surface left behind immediately after a tumor is cut out, ensuring an even and highly localized dose escalation across the tissue where microscopic cancer cells typically hide.

The low-dose brachytherapy dispersed over several weeks from the embedded cesium-131 seeds effectively targets residual cancer cells while limiting exposure to healthy brain tissue. The rapid dose fall-off characteristic of brachytherapy ensures that only a small portion of the surrounding brain is exposed to significant radiation, thereby minimizing toxicity and side effects.

Pruning Toxic Side Effects

The ROADS trial confirmed that improved clinical outcomes did not come at the cost of increased toxicity. Rates of serious treatment-related side effects and radiation necrosis, a critical late-stage risk for brain metastasis patients, remained virtually identical between the tile and standard radiation groups.

“Implanting the radioactive tiles at the time of surgery guarantees that patients receive their treatment immediately, along with focal dose escalation, thereby having meaningful impact on local tumor control,” said Weinberg. “From a patient standpoint, we’re showing that there’s almost four times the length of local control and an increase in overall survival.”

Practical Significance for Patients

The expedited return to systemic cancer therapies is another significant advantage of TBRT. Because patients treated with the collagen tiles complete their entire cranial radiation protocol in a single day, they can bypass the roadblock of a brain metastasis diagnosis and return to systemic cancer treatments earlier, protecting other parts of their body from further progression.

“These results are dramatically better than the current alternatives and provide improved patient convenience by getting them over the roadblock of a brain metastasis diagnosis more quickly,” said Beckham. “At the end of the day, being able to get them over that roadblock and back to managing their cancer overall seems to positively impact more than just their surgical outcome, which is really exciting and something we weren’t expecting to this magnitude.”

Future Outlook and Adoption

The researchers hope these results will accelerate TBRT guideline adoption and establish broader clinical rollout. Future work can determine how widely the technology can be applied in various clinical settings, potentially revolutionizing brain cancer treatment worldwide.